{"id":"W2794945244","doi":"10.1016/j.lungcan.2018.03.025","title":"Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting","year":2018,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Eli Lilly and Company","keywords":"Medicine; Oncology; Docetaxel; Internal medicine; Bevacizumab; Ramucirumab; Lung cancer; Nintedanib; Refractory (planetary science); Chemotherapy; Lung; Idiopathic pulmonary fibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000290372,0.0003695047,0.001016954,0.0008073705,0.0001426708,0.0005677895,0.0005049238,0.0005214061,0.00276985],"category_scores_gemma":[0.0005839042,0.000136524,0.000569448,0.0005933074,0.0001565342,0.0005223216,0.0002902267,0.001255772,0.0005126927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00028565,"about_ca_system_score_gemma":0.0005047635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006833242,"about_ca_topic_score_gemma":0.002530336,"domain_scores_codex":[0.9998999,0.00002263469,0.00001730078,0.00001764944,0.00003127262,0.00001126897],"domain_scores_gemma":[0.9998097,0.0001138524,0.00003846842,0.000003253305,0.00002390208,0.00001075439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001122755,0.00006380551,0.0002476638,0.01968859,0.0002526377,0.0001407101,0.00002936836,0.0002893595,0.0009493124,0.001236209,0.01923331,0.9577568],"study_design_scores_gemma":[0.000217592,0.0003325843,0.002942836,0.01753972,0.001203202,0.0033085,0.00007582812,0.0003178469,0.0008881931,0.002088871,0.971045,0.00003985866],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001652239,0.9990948,0.00004639057,0.0001597653,0.00007286725,0.000003661426,0.00001551733,0.000002704776,0.0004389929],"genre_scores_gemma":[0.00204867,0.9970406,0.0001288664,0.0002769591,0.0001056357,0.000006321497,0.00003942952,0.000001091379,0.0003525466],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00276985,"threshold_uncertainty_score":0.009266078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0180276582502401,"score_gpt":0.3736487933526319,"score_spread":0.3556211351023918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}